learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
5 / 12 resultslearn Fluridil
a topical anti-androgen with less systemic involvement
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
Research
5 / 1000+ results
research Revising the Role of the Androgen Receptor in Breast Cancer
The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research Synthesis and Application of Clinically Approved Small-Molecule Drugs Targeting Androgen Receptor
Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
research Antiandrogenic Activity of Riboflavin 5′-Phosphate (FMN) in 22Rv1 and LNCaP Human Prostate Cancer Cell Lines
Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
research Anti-Acne Agents Attenuate FGFR2 Signal Transduction in Acne
Anti-acne medications may work by reducing the activity of a protein involved in acne development.
Community Join
5 / 1000+ resultscommunity 21M with a nasty case of MPB; Heres what's on my radar for the future.
Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
community SCUBE3 and GT20029 could be the closet thing to a cure: Hair Follicle Regeneration and Protection Against DHT
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor has announced the results for their human Phase I trials of GT20029
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.